Last reviewed · How we verify

NCT03562845: TRANSBIO

Evaluation of Immunobiogram® as a Tool in Adjustment of Immunosuppressant Therapy for Renal Transplant

Completed Last updated 29 December 2023
What this trial tests

trial testing NA-Observational only in Kidney Transplantation in 164 participants. Completed in 31 May 2019.

Timeline
1 June 2018
Primary endpoint
30 April 2019
31 May 2019

Quick facts

Lead sponsorBiohope Scientific Solutions for Human Health, S.L.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment164
Start date1 June 2018
Primary completion30 April 2019
Estimated completion31 May 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Biohope Scientific Solutions for Human Health, S.L.

Who can join

Adults 25 to 69, any sex, with Kidney Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The trial is an observational, multi-center study to determine if a new blood test (Immunobiogram®) done after renal transplant can help predict how well the immune system is working and responding to a new kidney. These blood tests could, in the future, potentially guide how doctors manage patient's anti-rejection medication.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Kidney Transplantation

Currently open trials in the same condition.

Other Biohope Scientific Solutions for Human Health, S.L. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03562845.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing